A New Regulatory Path for Enforcing GLP-1 Compounding Safety and Protecting Public Health
Home Study Webinar
$20 Activity Fee
Topic Designator: 03 – Law | Credit: 1.5 contact hours Available through April 29, 2029
The strong demand for GLP-1 therapies has led several entities including med spas and wellness clinics to enter this niche and offer customized formulas beyond what is commercially available. This rise in GLP-1 compounding has resulted in state regulatory boards taking necessary action through the enforcement of compounding laws to protect the public from inappropriate or substandard practices, including compounding using research-grade active pharmaceutical ingredients (APIs). Participants will be provided with a scientific overview of compounding GLP-1 drug products with APIs and how to analyze an API certificate of analysis for appropriateness. The session will also focus on the regulatory and political landscape of GLP-1 compounding, including those related to the active pharmaceutical ingredients. Participants will also receive an update from states that have taken action to protect patients from inappropriate compounding of GLP-1s, particularly in med spa and wellness clinic settings.
This home study webinar is a recording of the live activity that was held on May 13, 2026.
Presenters
Marta E. Wosińska, PhD
Senior Fellow, Center on Health Policy at Brookings
Marta Wosinska is a senior fellow of economic studies at The Center on Health Policy at Brookings. She is a health care economist specializing in prescription drug markets and a leading expert on the economics of drug shortages. Marta has experience spanning top academic institutions, prominent think tanks, and federal agencies including FTC, FDA, and the HHS Office of Inspector General.
Thomas Kupiec, PhD
Chief Executive Officer, ARL Bio Pharma and DNA Solutions, Inc
Thomas Kupiec is the chief executive officer of ARL Bio Pharma and DNA Solutions, and the managing editor of the International Journal of Pharmaceutical Compounding. Thomas currently serves on the board of directors for several state and national boards spanning education, science, public safety, health, and community initiatives. Additionally, he provides consultation and expert witness testimony in the fields of forensic toxicology and pharmaceutical sciences, including litigation, patent infringement, and medication errors. Thomas received his PhD in pharmaceutical sciences from the University of Oklahoma Health Sciences Center College of Pharmacy.
Andrew Funk, PharmD
Director of Member Relations and Government Affairs, NABP
Andrew Funk is the director of Member Relations and Government Affairs at NABP. In this role, Andrew assists NABP’s member boards by providing them with the necessary resources to further their mission of protecting public health. Andrew also works with state and federal policy makers on matters related to the practice of pharmacy, medication distribution, and prescription monitoring programs. Prior to joining NABP, Andrew served as the executive director of the Iowa board of pharmacy.
Susan McCoy, RPh
Executive Director, Mississippi Board of Pharmacy
Susan McCoy is the executive director for the Mississippi Board of Pharmacy. She has 41 years of experience in various pharmacy practices, with a concentration on retail, as well as nine and a half years of experience as a compliance agent. Her experience includes collaboration with multiple federal and state agencies, various Mississippi health and regulatory boards, and state legislators. She has served on several NABP committees and was president of the Mississippi chapter of the National Association of Drug Diversion Investigators for four years. Susan received her pharmacy degree from the University of Mississippi’s School of Pharmacy.
